DESIGNED TO BE DIFFERENT
by minimising off-target effects in the treatment of B-cell malignancies21–24
Proven efficacy regardless of line of
therapy, genetic status and patient
populations25–29
A consistent safety profile
demonstrated across B-cell
malignancies for over five years1,28–31
Unmatched BTK inhibitor
dosing flexibility1,32–34